Literature DB >> 10567218

Functional and structural properties of lipid-associated apolipoprotein J (clusterin).

M Calero1, T Tokuda, A Rostagno, A Kumar, B Zlokovic, B Frangione, J Ghiso.   

Abstract

Apolipoprotein J (apoJ, clusterin) is a multifunctional protein normally associated with lipids in plasma and cerebrospinal fluid, and secreted as lipoparticles by hepatocytes and astrocytes. To investigate whether the structural and functional properties of apoJ are modulated upon binding to lipids, we prepared apoJ high-density lipoprotein (HDL)-like particles employing either synthetic or plasma HDL-derived lipids. The majority of the resulting lipoparticles contained one molecule of apoJ per particle and exhibited the same alpha2 electrophoretic mobility characteristic of apoJ-containing plasma HDL. Particle size seemed to be dependent on the presence of cholesterol in the lipid mixture and ranged from diameters of 10 nm in the presence of cholesterol to 20 nm in the absence of cholesterol. CD analysis and Fourier-transform infrared spectroscopy revealed similar changes in the apoJ secondary structure induced by its incorporation into lipoparticles, namely a decrease in alpha-helix content and an increase in beta-turn structures. Two functional assays, the binding interaction with Alzheimer's amyloid beta peptides and the inhibitory activity of the complement membrane-attack complex, did not detect any changes in apoJ activity following its lipidation (P>0.05). On the contrary, the binding affinity to the cellular receptor megalin was enhanced significantly (P<0.01) after the association with lipids; the K(d) value decreased from 78.8+/-10.7 nM for the delipidated form to 37. 0+/-7.3 nM for apoJ-HDL. Although it is not known whether the structural changes observed are directly responsible for the higher receptor-binding affinity, the data suggest that the complement inhibition and amyloid beta-binding motifs are located in areas of the molecule different from those involved in the apoJ-megalin interaction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567218      PMCID: PMC1220653     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes.

Authors:  N H Choi; T Mazda; M Tomita
Journal:  Mol Immunol       Date:  1989-09       Impact factor: 4.407

2.  SP-40,40 is an inhibitor of C5b-6-initiated haemolysis.

Authors:  B F Murphy; J R Saunders; M K O'Bryan; L Kirszbaum; I D Walker; A J d'Apice
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

3.  Changes in brain gene expression shared by scrapie and Alzheimer disease.

Authors:  J R Duguid; C W Bohmont; N G Liu; W W Tourtellotte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Purification and characterization of apolipoprotein J.

Authors:  H V de Silva; W D Stuart; Y B Park; S J Mao; C M Gil; J R Wetterau; S J Busch; J A Harmony
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

5.  The gene for SP-40,40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8.

Authors:  M Purrello; S Bettuzzi; C Di Pietro; E Mirabile; M Di Blasi; R Rimini; K H Grzeschik; C Ingletti; A Corti; G Sichel
Journal:  Genomics       Date:  1991-05       Impact factor: 5.736

6.  In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell death.

Authors:  S Bettuzzi; L Troiano; P Davalli; F Tropea; M C Ingletti; E Grassilli; D Monti; A Corti; C Franceschi
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

7.  Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat.

Authors:  P C May; M Lampert-Etchells; S A Johnson; J Poirier; J N Masters; C E Finch
Journal:  Neuron       Date:  1990-12       Impact factor: 17.173

8.  Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease.

Authors:  A M Lidström; N Bogdanovic; C Hesse; I Volkman; P Davidsson; K Blennow
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

9.  Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma.

Authors:  D E Jenne; B Lowin; M C Peitsch; A Böttcher; G Schmitz; J Tschopp
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

10.  Apolipoprotein J: structure and tissue distribution.

Authors:  H V de Silva; J A Harmony; W D Stuart; C M Gil; J Robbins
Journal:  Biochemistry       Date:  1990-06-05       Impact factor: 3.162

View more
  23 in total

Review 1.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

Review 2.  Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins.

Authors:  Andrew N Hoofnagle; Jay W Heinecke
Journal:  J Lipid Res       Date:  2009-10       Impact factor: 5.922

3.  Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.

Authors:  T Tokuda; M Calero; E Matsubara; R Vidal; A Kumar; B Permanne; B Zlokovic; J D Smith; M J Ladu; A Rostagno; B Frangione; J Ghiso
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

4.  Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults.

Authors:  Meredith N Braskie; Neda Jahanshad; Jason L Stein; Marina Barysheva; Katie L McMahon; Greig I de Zubicaray; Nicholas G Martin; Margaret J Wright; John M Ringman; Arthur W Toga; Paul M Thompson
Journal:  J Neurosci       Date:  2011-05-04       Impact factor: 6.167

5.  Kidney Diseases: The Age of Molecular Markers.

Authors:  Glaucia Luciano da Veiga; Beatriz da Costa Aguiar Alves; Matheus Moreira Perez; Joyce Regina Raimundo; Jéssica Freitas de Araújo Encinas; Neif Murad; Fernando Luiz Affonso Fonseca
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

7.  Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Authors:  Aynun N Begum; Fusheng Yang; Edmond Teng; Shuxin Hu; Mychica R Jones; Emily R Rosario; Walter Beech; Beverly Hudspeth; Oliver J Ubeda; Greg M Cole; Sally A Frautschy
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  Changes in protein structure and distribution observed at pre-clinical stages of scrapie pathogenesis.

Authors:  Ariane Kretlow; Qi Wang; Michael Beekes; Dieter Naumann; Lisa M Miller
Journal:  Biochim Biophys Acta       Date:  2008-06-14

9.  Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Authors:  Celia M Torres-Arancivia; Deborah Chang; William E Hackett; Joseph Zaia; Lawreen H Connors
Journal:  Biochemistry       Date:  2020-11-03       Impact factor: 3.162

Review 10.  Sex differences in Alzheimer's disease: Understanding the molecular impact.

Authors:  Carlos A Toro; Larry Zhang; Jiqing Cao; Dongming Cai
Journal:  Brain Res       Date:  2019-05-23       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.